| Literature DB >> 23314338 |
C K Konopka1, E N Morais, D Naidon, A M Pereira, M A Rubin, J F Oliveira, C F Mello.
Abstract
Hormone-mediated quiescence involves the maintenance of a decreased inflammatory responsiveness. However, no study has investigated whether labor induction with prostanoids is associated with changes in the levels of maternal serum hormones. The objective of this study was to determine whether labor induction with dinoprostone is associated with changes in maternal serum progesterone, estradiol, and estriol levels. Blood samples were obtained from 81 pregnant women at term. Sixteen patients had vaginal birth after spontaneous labor, 12 required cesarean section after spontaneous labor and 16 underwent elective cesarean. Thirty-seven patients had labor induction with dinoprostone. Eligible patients received a vaginal insert of dinoprostone (10 mg) and were followed until delivery. Serum progesterone (P4), estradiol (E2) and estriol (E3) levels and changes in P4/E2, P4/E3 and E3/E2 ratios were monitored from admission to immediately before birth, and the association of these measures with the resulting clinical classification outcome (route of delivery and induction responsiveness) was assessed. Progesterone levels decreased from admission to birth in patients who underwent successful labor induction with dinoprostone [vaginal and cesarean birth after induced labor: 23% (P < 0.001) and 18% (P < 0.025) decrease, respectively], but not in those whose induction failed (6.4% decrease, P > 0.05). Estriol and estradiol levels, P4/E2, P4/E3 and E3/E2 ratios did not differ between groups. Successful dinoprostone-induced labor was associated with reduced maternal progesterone levels from induction to birth. While a causal relationship between progesterone decrease and effective dinoprostone-induced labor cannot be established, it is tempting to propose that dinoprostone may contribute to progesterone withdrawal and favor labor induction in humans.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23314338 PMCID: PMC3854342 DOI: 10.1590/1414-431x20122453
Source DB: PubMed Journal: Braz J Med Biol Res ISSN: 0100-879X Impact factor: 2.590
Maternal age, gestational age, time between samplings, and parity of patients with and without dinoprostone treatment.
Data are reported as means ± SE or as median (interquatile range). There were no significant differences among groups for maternal age or gestational age (one-way ANOVA). *Time between blood samplings and parity were analyzed by the Kruskal-Wallis test. Different superscript letters indicate significant differences by the Dunn nonparametric multiple comparison test (P < 0.05).
Bishop scores at admission and immediately before birth of patients with and without dinoprostone treatment.
Data are reported as means ± SE and analyzed by the t-test for paired samples.
Figure 1Maternal serum levels of progesterone at admission and immediately before birth in patients with and without dinoprostone treatment. Sp. = spontaneous; Ind. = induced or induction. *P < 0.005 and **P < 0.025 compared to the respective admission mean for patients with and without dinoprostone treatment (two-way ANOVA followed by the F-test for simple effect).
Figure 2Possible mechanism by which dinoprostone contributes to progesterone withdrawal. An increased PR-A/PR-B ratio decreased progesterone (P4) activity by unsuppressing NF-κB-mediated responses, including COX-2 induction and increased prostanoid (PGE2 and PGF2) synthesis, which cause uterine contraction. Dinoprostone, a PGE2 analogue, decreases P4 levels by still unknown mechanisms, which may include decreased placenta P4 production/secretion contributing to P4 withdrawal. PR = progesterone receptor; NF-kB = transcription nuclear factor-κB; COX-2 = cyclooxygenase-2.